These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 6362866

  • 21. Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas.
    Yamasaki T, Handa H, Yamashita J, Watanabe Y, Namba Y, Hanaoka M.
    Cancer Res; 1984 May; 44(5):1776-83. PubMed ID: 6608988
    [Abstract] [Full Text] [Related]

  • 22. The gene therapy of cancer: transgenic immunotherapy.
    Zwiebel JA, Su N, MacPherson A, Davis T, Ojeifo JO.
    Semin Hematol; 1993 Oct; 30(4 Suppl 4):119-28; discussion 129. PubMed ID: 8303305
    [Abstract] [Full Text] [Related]

  • 23. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
    Dang Y, Disis ML.
    Ann N Y Acad Sci; 2009 Sep; 1174():81-7. PubMed ID: 19769740
    [Abstract] [Full Text] [Related]

  • 24. Tracking the elusive lymphocyte: methods of detection during adoptive immunotherapy.
    Skitzki JJ, Muhitch JB, Evans SS.
    Immunol Invest; 2007 Sep; 36(5-6):807-27. PubMed ID: 18161530
    [Abstract] [Full Text] [Related]

  • 25. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.
    Cancer Res; 1993 Mar 01; 53(5):1043-50. PubMed ID: 8439951
    [Abstract] [Full Text] [Related]

  • 26. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2.
    Luo Y, Wen YJ, Ding ZY, Fu CH, Wu Y, Liu JY, Li Q, He QM, Zhao X, Jiang Y, Li J, Deng HX, Kang B, Mao YQ, Wei YQ.
    Clin Cancer Res; 2006 Mar 15; 12(6):1813-9. PubMed ID: 16551866
    [Abstract] [Full Text] [Related]

  • 27. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
    Peres E, Wood GW, Poulik J, Baynes R, Sood S, Abidi MH, Klein J, Bhambhani K, Dansey R, Abella E.
    Neuropediatrics; 2008 Jun 15; 39(3):151-6. PubMed ID: 18991194
    [Abstract] [Full Text] [Related]

  • 28. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.
    Gomez GG, Hutchison RB, Kruse CA.
    Cancer Treat Rev; 2001 Dec 15; 27(6):375-402. PubMed ID: 11908930
    [Abstract] [Full Text] [Related]

  • 29. Antitumor immunity induced by laser immunotherapy and its adoptive transfer.
    Chen WR, Singhal AK, Liu H, Nordquist RE.
    Cancer Res; 2001 Jan 15; 61(2):459-61. PubMed ID: 11212231
    [Abstract] [Full Text] [Related]

  • 30. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J, Chen Y, Moyana T.
    Cancer Gene Ther; 2000 Jul 15; 7(7):1023-33. PubMed ID: 10917205
    [Abstract] [Full Text] [Related]

  • 31. Harnessing self-reactivity in cancer immunotherapy.
    Schoenberger SP, Sercarz EE.
    Semin Immunol; 1996 Oct 15; 8(5):303-9. PubMed ID: 8956459
    [Abstract] [Full Text] [Related]

  • 32. [Pros and cons of the use of immunotherapeutic procedures with special reference to adoptive immunotherapy in proliferative diseases].
    Schneiberg K.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980 Oct 15; 107(3):337-57. PubMed ID: 6159273
    [Abstract] [Full Text] [Related]

  • 33. Cancer immunotherapy: a treatment for the masses.
    Blattman JN, Greenberg PD.
    Science; 2004 Jul 09; 305(5681):200-5. PubMed ID: 15247469
    [Abstract] [Full Text] [Related]

  • 34. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J, Hu P, Khawli LA, Epstein AL.
    Cancer Res; 2003 Dec 01; 63(23):8384-92. PubMed ID: 14679000
    [Abstract] [Full Text] [Related]

  • 35. Therapy with allogeneic immune peritoneal cells.
    Dullens HF, Den Otter W.
    Cancer Res; 1974 Jul 01; 34(7):1726-30. PubMed ID: 4833917
    [No Abstract] [Full Text] [Related]

  • 36. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 37. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
    Rossi GR, Mautino MR, Awwad DZ, Husske K, Lejukole H, Koenigsfeld M, Ramsey WJ, Vahanian N, Link CJ.
    J Immunother; 2008 Feb 01; 31(6):545-54. PubMed ID: 18528300
    [Abstract] [Full Text] [Related]

  • 38. Immune control of neoplasia by adoptive transfer of macrophages: potentiality for antigen presentation and gene transfer.
    Bartholeyns J, Lopez M.
    Anticancer Res; 1994 Feb 01; 14(6B):2673-6. PubMed ID: 7872699
    [Abstract] [Full Text] [Related]

  • 39. Immunotherapy of a murine lymphoma by adoptive transfer of syngeneic macrophages activated with bisantrene.
    Wang BS, Lumanglas AL, Durr FE.
    Cancer Res; 1986 Feb 01; 46(2):503-6. PubMed ID: 3940628
    [Abstract] [Full Text] [Related]

  • 40. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I, Pedrazzoli P, Tullio C, Montini E, La Grotteria MC, Schiavo R, Perotti C, Locatelli F, Carretto E, Maccario R, Siena S, Montagna D.
    Cytotherapy; 2007 Feb 01; 9(5):499-507. PubMed ID: 17786611
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.